442514-22-9

Basic information

• Product Name: tert-Butyl 3-(methylamino)propylcarbamate
• Synonyms: Boc-3-methylamino-propylcarbamate;tert-Butyl 3-(methylamino)propylcarbamate;1-BOC-AMINO-3-METHYLAMINO-PROPANE-HCl;Boc-3-MethylaMino-propylcarbaMate HCl;Tert-butyl N-[3-(MethylaMino)propyl]carbaMate;(3-Methylamino-propyl)-carbamic acid tert-butyl ester;3-N-Boc-N1-methylpropane-1,3-diamine;N-Boc-3-(methylamino)propanamine
• CAS NO: 442514-22-9
• Molecular Formula: C₉H₂₀N₂O₂
• Molecular Weight: 188.27
• Mol File: 442514-22-9.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 280.3 °C at 760 mmHg
• Flash Point: 123.3 °C
• Appearance: /
• Density: 0.95 g/cm³
• Vapor Pressure: 0.00381mmHg at 25°C
• Refractive Index: 1.444
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 12.82±0.46(Predicted)
• CAS DataBase Reference: tert-Butyl 3-(methylamino)propylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 3-(methylamino)propylcarbamate(442514-22-9)
• EPA Substance Registry System: tert-Butyl 3-(methylamino)propylcarbamate(442514-22-9)

Safety Data

• Hazardous Substances Data: 442514-22-9(Hazardous Substances Data)

Usage

InChI:InChI=1/C9H20N2O2/c1-9(2,3)13-8(12)11-7-5-6-10-4/h10H,5-7H2,1-4H3,(H,11,12)

Upstream product

• 530-62-1 1,1'-carbonyldiimidazole 
• 6291-84-5 N-Methyl-1,3-propanediamine 
• 75-65-0 tert-butyl alcohol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1158721-71-1 N-Boc-(3-Cbz-methylaminopropyl)amine 
• 83948-53-2 3-bromopropylamine tert-butylcarbamate 
• 74-89-5 methylamine 
• 49761-82-2 tert-butyl 1H-imidazole-1-carboxylate 

Downstream Products

• 909804-19-9 (2-{[(3-tert-butoxycarbonylamino-propyl)-methyl-amino]-methyl}-phenyl)-boronic acid 
• 676351-10-3 tert-butyl-3-{methyl[3-(1-oxido-1,2,4-benzotriazin-3-yl)propyl]amino}propylcarbamate 
• 289701-05-9 N-[3-(tert. butyloxycarbonylamino)-propyl]-sarcosine ethyl ester 

Relevant articles and documents

LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS

Compounds are provided having the following structure (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1a, R1b, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6, R7, R8, L1, L2, G1, G2, G3, a, b, c and d are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

LIPID DELIVERY OF THERAPEUTIC AGENTS TO ADIPOSE TISSUE

A method of treating a disease mediated by protein expression in adipose tissue by intraperitoneally administering a composition comprising a lipid nanoparticle encapsulating or associated with a therapeutic agent (e.g., a nucleic acid), thereby delivering the therapeutic agent to adipose tissue of the subject and altering protein expression in the adipose tissue is provided herein. A method for delivering a therapeutic agent to adipose tissue of a subject in need thereof is also provided.

PRO-DRUGS FOR CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS

Pro-drugs containing an electron withdrawing substituent, as defined in the specification, are useful in a method for providing a patient with post administration-activated, controlled release of a biologically active compound.